Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

465
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
465

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Distribution, severity, and management of joint pain in patients with acromegaly.

European journal of endocrinology·2026
Same author

Management of endocrine disease: update on the management of pituitary apoplexy.

European journal of endocrinology·2026
Same author

Approach to the Patient with Cushing's Syndrome: Use of Anticoagulation Therapy.

The Journal of clinical endocrinology and metabolism·2025
Same author

EndoCompass project: research roadmap for pituitary and neuroendocrine tumor endocrinology.

European journal of endocrinology·2025
Same author

Consensus on acromegaly therapeutic outcomes: an update.

Nature reviews. Endocrinology·2025
Same journal

Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.

Pituitary·2026
Same journal

Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?

Pituitary·2026
Same journal

Gauze swabbing technique for safe dissection of pituitary tumors.

Pituitary·2026
Same journal

Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas.

Pituitary·2026
Same journal

Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.

Pituitary·2026
Same journal

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.0K

Refractory lactotroph adenomas.

Sandrine A Urwyler1,2,3, Niki Karavitaki4,5,6

  • 1Institute of Metabolism and Systems Research (ISMR), College of Medical and Dental Sciences, University of Birmingham, IBR Tower, Level 2, Birmingham, B15 2TT, UK.

Pituitary
|March 17, 2023
PubMed
Summary
This summary is machine-generated.

Dopamine agonist-resistant prolactinomas require tailored management, including alternative treatments like temozolomide or immune checkpoint inhibitors for aggressive cases. Further research is needed to assess other therapeutic options for these challenging tumors.

Keywords:
Aggressive prolactinomaDopamine agonist resistanceMalignant prolactinomaProlactinoma

More Related Videos

Measuring Lactase Enzymatic Activity in the Teaching Lab
04:41

Measuring Lactase Enzymatic Activity in the Teaching Lab

Published on: August 6, 2018

114.0K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.4K

Related Experiment Videos

Last Updated: Aug 6, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.0K
Measuring Lactase Enzymatic Activity in the Teaching Lab
04:41

Measuring Lactase Enzymatic Activity in the Teaching Lab

Published on: August 6, 2018

114.0K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.4K

Area of Science:

  • Endocrinology
  • Oncology
  • Pituitary Disorders

Background:

  • A subset of prolactinomas, a type of pituitary tumor, exhibit resistance to dopamine agonists (DA).
  • These resistant adenomas can display aggressive or malignant behavior, posing significant management challenges.
  • The underlying mechanisms of DA resistance and aggressive behavior are not fully understood.

Purpose of the Study:

  • To review current management strategies for dopamine agonist-resistant prolactinomas.
  • To discuss therapeutic options for aggressive and malignant prolactinomas.
  • To highlight the need for further research into novel treatment modalities.

Main Methods:

  • Literature review of studies on prolactinoma management.
  • Analysis of treatment outcomes for resistant and aggressive pituitary adenomas.
  • Discussion of emerging therapeutic approaches.

Main Results:

  • Switching to alternative dopamine agonists is a primary strategy for DA-resistant prolactinomas.
  • Surgery and radiotherapy are established options, often used in combination.
  • Temozolomide and immune checkpoint inhibitors show promise for aggressive or malignant cases.

Conclusions:

  • Management of DA-resistant prolactinomas necessitates a multidisciplinary approach.
  • Established treatments include alternative DAs, surgery, and radiotherapy.
  • Emerging therapies like temozolomide and immune checkpoint inhibitors offer new hope, with other treatments requiring further evaluation.